Abstract
Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Current Vascular Pharmacology
Title: Pleiotropic Effects of ARB on Dyslipidemia
Volume: 9 Issue: 2
Author(s): Isao Taguchi, Teruo Inoue, Migaku Kikuchi, Shigeru Toyoda, Takuo Arikawa, Shichiro Abe and Koichi Node
Affiliation:
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Abstract: Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Export Options
About this article
Cite this article as:
Taguchi Isao, Inoue Teruo, Kikuchi Migaku, Toyoda Shigeru, Arikawa Takuo, Abe Shichiro and Node Koichi, Pleiotropic Effects of ARB on Dyslipidemia, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519336
DOI https://dx.doi.org/10.2174/157016111794519336 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets A Versatile Stability-indicating Liquid Chromatographic Method for the Simultaneous Determination of Atenolol, Hydrochlorothiazide and Chlorthalidone
Current Pharmaceutical Analysis Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology New Developments in Oral Vaccines and Mucosal Adjuvants
Recent Patents on Inflammation & Allergy Drug Discovery NPY and NPY Receptors in Vascular Remodeling
Current Topics in Medicinal Chemistry Flaxseed for Health and Disease: Review of Clinical Trials
Combinatorial Chemistry & High Throughput Screening Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research An Overview of Olive Oil Biomolecules
Current Biotechnology Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Animal Models to Study Plaque Vulnerability
Current Pharmaceutical Design Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma
Current Pharmaceutical Design Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design